139 related articles for article (PubMed ID: 25252701)
1. On the margins of aid orthodoxy: the Brazil-Mozambique collaboration to produce essential medicines in Africa.
Russo G; de Oliveira L; Shankland A; Sitoe T
Global Health; 2014 Sep; 10():70. PubMed ID: 25252701
[TBL] [Abstract][Full Text] [Related]
2. Changing global essential medicines norms to improve access to AIDS treatment: lessons from Brazil.
Nunn A; Fonseca ED; Gruskin S
Glob Public Health; 2009; 4(2):131-49. PubMed ID: 19333805
[TBL] [Abstract][Full Text] [Related]
3. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
4. Expanding drug access in Brazil: lessons for Latin America and Canada.
Cohen JC
Can J Public Health; 2006; 97(6):I15-8. PubMed ID: 17203728
[TBL] [Abstract][Full Text] [Related]
5. Local production of pharmaceuticals in Africa and access to essential medicines: 'urban bias' in access to imported medicines in Tanzania and its policy implications.
Mujinja PG; Mackintosh M; Justin-Temu M; Wuyts M
Global Health; 2014 Mar; 10():12. PubMed ID: 24612518
[TBL] [Abstract][Full Text] [Related]
6. Brazil-Africa technical cooperation in health: what's its relevance to the post-Busan debate on 'aid effectiveness'?
Russo G; Cabral L; Ferrinho P
Global Health; 2013 Jan; 9():2. PubMed ID: 23339681
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical Services and comprehensiveness 30 years after the advent of Brazil's Unified Health System.
Bermudez JAZ; Esher A; Osorio-de-Castro CGS; Vasconcelos DMM; Chaves GC; Oliveira MA; Silva RMD; Luiza VL
Cien Saude Colet; 2018 Jun; 23(6):1937-1949. PubMed ID: 29972501
[TBL] [Abstract][Full Text] [Related]
8. Health-industry linkages for local health: reframing policies for African health system strengthening.
Mackintosh M; Mugwagwa J; Banda G; Tibandebage P; Tunguhole J; Wangwe S; Karimi Njeru M
Health Policy Plan; 2018 May; 33(4):602-610. PubMed ID: 29562286
[TBL] [Abstract][Full Text] [Related]
9. The public production of medicines compared to the National Policy of Medicines and the burden of disease in Brazil.
Figueiredo TA; Schramm JMA; Pepe VLE
Cad Saude Publica; 2017 Sep; 33(9):e00179815. PubMed ID: 28977283
[TBL] [Abstract][Full Text] [Related]
10. Retail prices of essential drugs in Brazil: an international comparison.
Nóbrega Ode T; Marques AR; de Araújo AC; Karnikowski MG; Naves Jde O; Silver LD
Rev Panam Salud Publica; 2007 Aug; 22(2):118-23. PubMed ID: 17976278
[TBL] [Abstract][Full Text] [Related]
11. The AIDS Epidemic and the Mozambican Society of Medicines: an analysis of Brazilian cooperation.
Fedatto MDS
Cien Saude Colet; 2017 Jul; 22(7):2295-2304. PubMed ID: 28724011
[TBL] [Abstract][Full Text] [Related]
12. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
13. How can a policy foster local pharmaceutical production and still protect public health? Lessons from the health-industry complex in Brazil.
da Fonseca EM
Glob Public Health; 2018 Apr; 13(4):489-502. PubMed ID: 29098942
[TBL] [Abstract][Full Text] [Related]
14. The UNESCO Bioethics Declaration 'social responsibility' principle and cost-effectiveness price evaluations for essential medicines.
Faunce TA
Monash Bioeth Rev; 2005 Jul; 24(3):10-9. PubMed ID: 16302317
[TBL] [Abstract][Full Text] [Related]
15. Brazil's fight against AIDS and its implications for global health governance.
Wogart JP; Calcagnotto G
Healthc Q; 2006; 9(1):76-89. PubMed ID: 16548439
[TBL] [Abstract][Full Text] [Related]
16. Access to essential medicines: a Hobbesian social contract approach.
Ashcroft RE
Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
[TBL] [Abstract][Full Text] [Related]
17. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
18. Basic survival needs and access to medicines--coming to grips with TRIPS: conversion + calculation.
Van Puymbroeck RV
J Law Med Ethics; 2010; 38(3):520-49. PubMed ID: 20880239
[TBL] [Abstract][Full Text] [Related]
19. The performance and problems of the Turkish pharmaceutical industry: is there a need to develop a national drug policy?
Kisa A
J Med Syst; 2001 Oct; 25(5):309-18. PubMed ID: 11508904
[TBL] [Abstract][Full Text] [Related]
20. Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.
Hale VG; Woo K; Lipton HL
Health Aff (Millwood); 2005; 24(4):1057-63. PubMed ID: 16012146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
